Teriparatide and Raloxifene Reduce the Risk of New Adjacent Vertebral Fractures in Postmenopausal Women with Osteoporosis: Results from Two Randomized Controlled Trials

Bouxsein, Mary L.; Peiqi Chen; Glass, Emmett V.; Kallmes, David F.; Delmas, Pierre D.; Mitlak, Bruce H.
June 2009
Journal of Bone & Joint Surgery, American Volume;Jun2009, Vol. 91-A Issue 6, p1329
Academic Journal
Background: Vertebral fractures increase the risk of new vertebral fractures; however, we are not aware of any study addressing the risk of new vertebral fractures adjacent to existing vertebral fractures. Therefore, we sought to determine the influence of the number and severity of prevalent (preexisting) vertebral fractures on the risk of new adjacent vertebral fractures and to determine whether teriparatide (rhPTH [recombinant human parathyroid hormone] [1-34]) or raloxifene treatment reduces the incidence of adjacent vertebral fractures in postmenopausal women with osteoporosis. Methods: Data from the Fracture Prevention Trial and the Multiple Outcomes of Raloxifene Evaluation trial were analyzed to determine the incidences of new adjacent and new nonadjacent vertebral fractures in the placebo groups and the effect of treatment with raloxifene and ten paratide on the incidence of new adjacent vertebral fractures as compared with that of new nonadjacent vertebral fractures. Results: Of 1226 untreated postmenopausal women with one or more prevalent vertebral fractures at baseline, 196 (16.0%) had a total of 292 new vertebral fractures during the two-year follow-up period, with 108(8.8%) of the 1226 women having at least one new fracture adjacent to a prevalent fracture. Of the 292 new vertebral fractures, 136 (47%) were adjacent to a previously existing vertebral fracture. The risk of a new adjacent vertebral fracture was 2.5-fold higher than the risk of a new nonadjacent vertebral fracture (4.03% compared with 1.59%). The incidence of new adjacent vertebral fractures increased with both the number and the severity of prevalent vertebral fractures. Teriparatide reduced the risk of any new, new adjacent, and new nonadjacent vertebral fractures by 72%, 75%, and 70%, respectively, compared with the rates in the placebo group. Similarly, compared with the placebo, raloxifene treatment reduced the risk of any new vertebral fracture, new adjacent vertebral fracture, and new nonadjacent vertebral fracture by 54%, 54%, and 53%, respectively. Conclusions: In untreated postmenopausal women with osteoporosis, nearly half of the incident vertebral fractures occur adjacent to an existing vertebral fracture. Both teriparatide and raloxifene can significantly reduce the occurrence of new adjacent and nonadjacent vertebral fractures.


Related Articles

  • Six and Twelve Month Changes in Bone Turnover are Related to Reduction in Vertebral Fracture Risk During 3 Years of Raloxifene Treatment in Postmenopausal Osteoporosis. Bjarnason, N. H.; Sarkar, S.; Duong, T.; Mitlak, B.; Delmas, P. D.; Christiansen, C. // Osteoporosis International;Nov2001, Vol. 12 Issue 11, p922 

    : We studied the relationship between change in bone turnover and vertebral fracture risk during raloxifene therapy using 3-year data from the MORE trial, where 2622 of the 7705 randomized women had measurement of bone markers at baseline and after 6 and 12 months participation. Change in bone...

  • Carotid Artery Intima-Media Thickness after Raloxifene Treatment. Mack, Wendy J.; Dhungana, Bala; Dowsett, Sherie A.; Keech, Cheryl A.; Mei Feng; Yanjie Li; Hodis, Howard N. // Journal of Women's Health (15409996);Apr2007, Vol. 16 Issue 3, p370 

    Background: Raloxifene, a selective estrogen receptor modulator (SERM), decreases total and low-density lipoprotein cholesterol (LDL-C) in postmenopausal women and inhibits increases in intima-media thickness (IMT) in animal models. We tested whether up to 8 years exposure to raloxifene had an...

  • Raloxifene and cognition.  // Caribbean Health;Oct2001, Vol. 4 Issue 5, p33 

    The article provides an overview on the study regarding the cognitive function in postmenopausal women treated with raloxifene. The study primarily discusses the potential role of raloxifene, a selective oestrogen-receptor modulators, towards the cognitive performance of postmenopausal women...

  • The future of the new selective estrogen receptor modulators. Palacios, Santiago // Menopause International;Mar2007, Vol. 13 Issue 1, p27 

    Selective estrogen receptor modulators (SERMs) are compounds that display mixed estrogen agonist/antagonist activity. Currently, four SERMs are licensed for clinical use: tamoxifen, toremifene, clomifene and raloxifene. The STAR and RUTH trials have provided useful data about the potential role...

  • raloxifene. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p648 

    An encyclopedia entry for "raloxifene" is presented. It refers to a drug that is used to prevent and cure postmenopausal osteoporosis. It is noted that the drug has no beneficial effects on problems experienced during menopause, such as hot flushes. On the other hand, it can increase risk of...

  • Raloxifene: Mechanism of Action, Effects on Bone Tissue, and Applicability in Clinical Traumatology Practice. Rey, Jose R. Caeiro; Cervino, Eduardo Vaquero; Rentero, Maria Luz; Crespo, Emilio Calvo; Álvaro, Angel Oteo; Casillas, Marta // Open Orthopaedics Journal;2009, Vol. 3, p14 

    Raloxifene, a member of the class of selective estrogen receptor modulators (SERM), reproduces the beneficial effects of estrogens on the skeletal systems, without the negative effects estrogens on breast and endometrium. This is a review article summarizing its mechanism, effects on bone and...

  • Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study. Ferrari, Serge; Nakamura, Toshitaka; Hagino, Hiroshi; Fujiwara, Saeko; Lange, Jeffrey; Watts, Nelson // Journal of Bone & Mineral Metabolism;Sep2011, Vol. 29 Issue 5, p561 

    This study examined patients' risk profiles and adherence to treatment in relation to the effect of risedronate and raloxifene on hip fracture incidence. Administrative billing data were used to follow two cohorts of women aged 65 and older after starting therapy with either risedronate ( n =...

  • Osteoporosis: overview and pipeline. Yasothan, Uma; Kar, Santwana // Nature Reviews Drug Discovery;Sep2008, Vol. 7 Issue 9, p725 

    The article provides information about osteoporosis. It is a disabling skeletal disorder characterized by decreased bone strength, predisposing patients to increased risk bone fracture. It states that it is a gradual and painless process therefore it is diagnosed only after occurrence of a...

  • Effects of Raloxifene on Fracture Severity in Postmenopausal Women with Osteoporosis: Results from the MORE Study. Siris, E.; Adachi, J. D.; Lu, Y.; Fuerst, T.; Crans, G. G.; Wong, M.; Harper, K. D.; Genant, H. K. // Osteoporosis International;Nov2002, Vol. 13 Issue 11, p907 

    : Raloxifene reduces the risk of new vertebral fractures, but its effect on the severity of these new fractures has not been determined. The MORE (Multiple Outcomes of Raloxifene Evaluation) trial studied the effects of placebo, raloxifene 60 or 120 mg/day in 7705 postmenopausal women with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics